Reference

  1. Kelber, O ., F . Gaedcke, B . Steinhoff and H . Winterhoff “Ethanol in herbal medicinal products for children .” PharmInd, 2008. 70(9): 1124–7.
  2. Pilichiewicz, A . N ., M . Horowitz, G . J . Holtmann, N . J . Talley and C . Feinle-Bisset "Relationship between symptoms and dietary patterns in patients with functional dyspepsia ." Clin Gastroenterol Hepatol, 2009. 7(3): 317-22.
  3. von Arnim, U ., U . Peitz, B . Vinson, K . J . Gundermann and P . Malfertheiner “STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study.” Am J Gastroenterol, 2007. 102(6): 1268–1275 .
  4. Abdel-Aziz, H ., M . Schneider, W . Neuhuber, A . M . Kassem, S . Khailah, J . Muller, H . Gamaleldeen, A . Khairy, M . T . Khayyal, A . Shcherbakova, T . Efferth and G . Ulrich-Merzenich “GPR84 and TREM-1 signaling contribute to the pathogenesis of reflux esophagitis.” Mol Med, 2015. 21(1): 1011–1024.
  5. Abdel-Aziz, H ., O . Kelber, G . Lorkowski and M . Storr “Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast® .” Planta Med, 2017. 83(14/15): 1130–1140.
  6. Adarsh, M . B ., S . K . Sharma, K . K . Prasad, V . Dhir, S . Singh and S . K . Sinha " Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis." JGH Open, 2019. 3(3): 206-209.
  7. Allam, S ., D . Krueger, I . E . Demir, G . Ceyhan, F . Zeller and M . Schemann “Extracts from peppermint leaves, lemon balm leaves and in particular angelica roots mimic the pro-secretory action of the herbal preparation STW 5 in the human intestine.” Phytomedicine, 2015. 22(12): 1063–1070.
  8. Allescher, H . D . and H . Abdel-Aziz “Mechanism of Action of STW 5 in Functional Dyspepsia and IBS: The Origin of Multi-Target.” Dig Dis, 2017. 35 (Suppl 1): 18–24.
  9. Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy." Phytomed, 2006. 13 SV 2-11.
  10. Allescher, H . D. "Functional dyspepsia - A multicausal disease and its therapy." Phytomedicine, 2006. 13 SV 2-11.
  11. Ammon, H . P ., O . Kelber and S . N . Okpanyi “Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle .” Phytomedicine, 2006. 13 (Suppl 5): 67–74.
  12. Angelicae radix, ESCOP monographs 2009.
  13. Anisi Fructus, ESCOP monographs 2014.
  14. Annibale. B ., G . Esposito and E . Lahner " A current clinical overview of atrophic gastritis." Expert Rev Gastroenterol Hepatol, 2020. 14(2): 93-102.
  15. Balaban, C . D . and B . J . Yates "What is nausea? A historical analysis of changing views." Auton Neurosci, 2017. 202: 5-17.
  16. Berg, L . K ., E . Fagerli, M . Martinussen, A . O . Myhre, J . Florholmen and R . Goll "Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test." Scand J Gastroenterol, 2013. 48(8): 936-43.
  17. Bhatia, V . and R . K . Tandon "Stress and the gastrointestinal tract ." J Gastroenterol Hepatol, 2005. 20(3): 332-9.
  18. Bleimann, H ., R . Hartmann "Therapy of Gastrointestinal Functional Disorders with Iberogast® ." Der Kassenarzt, 1983; 23:52-59.
  19. Boeckxstaens, G ., M . Camilleri, D . Sifrim, L . A . Houghton, S . Elsenbruch, G . Lindberg, F . Azpiroz and H . P . Parkman "Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation ." Gastroenterology, 2016. 150: 1292-1304 .
  20. Boland, M . "Human digestion - a processing perspective ." J Sci Food Agric, 2016. 96: 2275-283.
  21. Bonaterra, G . A ., O . Kelber, D . Weiser and R . Kinscherf “Mechanisms of the antiproliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro.” Phytomedicine, 2013. 20(8–9): 691–698.
  22. Bonaterra, G ., R . Kinscherf, O . Kelber, D . Weiser and J . Metz “Antiinflammatorische und antiproliferative Wirkung von Iberogast® in vitro.” Z Gastroenterol, 2008. 46(09): P352.
  23. Braden, B ., W . Caspary, N . Börner, B . Vinson and A . R . J . Schneider “Clinical effects of STW 5 (Iberogast®) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis.” Neurogastroenterology & Motility, 2009. 21(6): 632–e625.
  24. Bredenoord, A . J . and A . J . P . Smout "Physiologic and pathologic belching ." Clin Gastroenterol Hepatol, 2007. 5(7): 772-5.
  25. Bremer, W ., F . Fischer and K . Nicolay "Gastrointestinal Illnesses - Therapy with Iberogast® " Z. Allg. Med., 1983. 59: 1706-1709.
  26. Brückel, M . H ., W . Gisevius "Iberis Amara Helps in Cases of Functional Stomach Complaints." Ärztl. Praxis, 1984. 36: 494.
  27. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rabbit.” 2003. Sequani Study no: VEB0003.
  28. Burns, L . M . “Oral (gavage) developmental toxicity dose range finding study in the rat.” 2003 . Sequani Study no: VEB0006 [Module 4 .2 .3 .5 .1 .3].
  29. Burns, L . M . “Oral (gavage) developmental toxicity study in the rabbit.” 2003. Sequani Study no: VEB0004.
  30. Burns, L . M . “Oral (gavage) developmental toxicity study in the rat.” 2003. Sequani Study no: VEB0008 [Module 4 .2 .3 .5 .1 .2].
  31. Burns, L . M . “Oral (gavage) fertility and general reproductive performance dose ranging study in the rat .” 2003. Sequani Study no: VEB0005 [Module 4 .2 .3 .5 .1 .1].
  32. Burns, L . M . “Oral (gavage) maximum tolerated dose (MTD) study in the rabbit .” 2003. Sequani Study no: VEB0002 .
  33. Burns, L . M . “Oral (gavage) pre- and post-natal developmental toxicity study in the rat .” 2003. Study no: VEB0009 [Module 4 .2 .3 .5 .3 .1].
  34. Burri, E ., E . Barba, J . W . Huaman, D . Cisternas, A . Accarino, A . Soldevilla, J . R . Malagelada, and F . Azpiroz "Mechanisms of postprandial abdominal bloating and distension in functional dyspepsia." Gut, 2014 . 63(3): 395-400.
  35. Bustos, M ., R . Venkataramanan and Steve Caritis "Nausea and vomiting of pregnancy - What's new? " Auton Neurosci, 2017. 202: 62-72.
  36. Bytzer, P . and N . J . Talley “Dyspepsia .” Ann Intern Med, 2001 . 134(9 Pt 2): 815–822.
  37. Camilleri, M ., B . Coulie and J . F . Tack “Visceral hypersensitivity: facts, speculations, and challenges.” Gut, 2001. 48(1): 125–131.
  38. Carvalho, R . V . B ., S . L . S . Lorena, J . R . de Souza Almeida and M . A . Mesquita "Food intolerance, diet composition, and eating patterns in functional dyspepsia patients." Dig Dis Sci, 2010. 55(1): 60-5.
  39. Carvi fructus, ESCOP monographs 2003.
  40. Catassi, G ., E . Lionetti, S . Gatti and C . Catassi "The Low FODMAP Diet: Many Question Marks for a Catchy Acronym." Nutrients, 2017. 9(3): 292.
  41. Surdea/Blaga, T,D.E. Negrutiu, M.Palage and D.L. Dimitrascu @Food and Gastroesophageal Reflux Disease.(Curr Med Chem, 2019. 26(19): 3497-3511.

Iberohexa

Više informacija
Proizvod Iberohexa, lišće na pozadini
Iberis amara

Iberohexa: Sveobuhvatno djelovanje na simptome funkcionalne dispepsije

Iskoristite moć prirode uz 6 ljekovitih biljaka koje djeluju zajedno. Učinkovito, klinički dokazano rješenje.

Otkrijte još

Imate li pitanja o lijeku Iberohexa?

Ovdje ćete pronaći brzi pregled najvažnijih tema.

Otkrijte još
Stresni probavni simptomi? Iberohexa može pomoći

Stresni probavni simptomi? Iberohexa može pomoći.

Gastrointestinalni problemi mogu značajno narušiti svakodnevni život. Saznajte više o tome zašto se oni javljaju i što možete učiniti da ih se riješite.

Otkrijte još